# Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

> **NCT00827138** · PHASE1 · COMPLETED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 57 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** DCC-2036

## Key facts

- **NCT ID:** NCT00827138
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827138, "Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00827138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*